Pfizer's blockbuster ADC Adcetris nabs FDA approval to treat large B-cell lymphoma

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green light to treat large B-cell lymphoma (LBCL).